Rankings
▼
Calendar
VRTX Q1 2023 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
VRTX
Vertex Pharmaceuticals Incorporated
$129B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2.4B
+13.2% YoY
Gross Profit
$2.1B
88.8% margin
Operating Income
$779M
32.8% margin
Net Income
$700M
29.5% margin
EPS (Diluted)
$2.69
QoQ Revenue Growth
+3.1%
Cash Flow
Operating Cash Flow
$900M
Free Cash Flow
$858M
Stock-Based Comp.
$122M
Balance Sheet
Total Assets
$19.0B
Total Liabilities
$4.5B
Stockholders' Equity
$14.4B
Cash & Equivalents
$9.3B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.4B
$2.1B
+13.2%
Gross Profit
$2.1B
$1.9B
+13.8%
Operating Income
$779M
$1.0B
-25.2%
Net Income
$700M
$762M
-8.2%
Revenue Segments
TRIKAFTA/KAFTRIO
$2.1B
88%
KALYDECO
$125M
5%
ORKAMBI
$123M
5%
SYMDEKO/SYMKEVI
$31M
1%
Geographic Segments
UNITED STATES
$1.4B
59%
Europe
$807M
34%
Other, Non U.S.
$164M
7%
← FY 2023
All Quarters
Q2 2023 →